Timeline, a Swiss Longevity Biotech, Secures Pivotal Financing Round with Support from Strategic Global Industry Leaders, including L’Oréal and Nestlé
Timeline, a consumer health biotech company at the forefront of developing innovative solutions for healthy aging and longevity, today announces that it raised CHF 56M (USD 66M) in an oversubscribed Series D financing round. This marks a significant milestone for the company and includes strategic investments from two global industry leaders—L’Oréal and Nestlé.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240117576326/en/
Timeline Longevity Products (Photo: Timeline)
The financing round was led by BOLD (Business Opportunities for L’Oréal Development), L'Oréal Groupe’s strategic innovation venture capital fund, underscoring investors confidence in the company's proprietary technology, Mitopure®, to help people live healthier for longer. Mitopure® is backed by over 15 years of research and is clinically proven to target a key cellular longevity pathway, by recycling and renewing the powerhouses inside cells, the mitochondria. Optimal mitochondrial function is essential for maintaining cellular energy which supports muscle strength, cognition, immune resilience, skin vitality and other important benefits, offering a comprehensive approach to promoting healthspan.
The support of these industry leaders and the funds raised will be used to build Timeline into a leading longevity consumer health brand by expanding the science, product categories, and markets across food, beauty and health sectors.
"This strategic collaboration reflects the breakthrough multidimensional approach that we've always believed is necessary to make meaningful advancements for longevity and healthspan." said Patrick Aebischer, Co-Founder and Chairman of Timeline “I want to thank L’Oréal, Nestlé and our longstanding investors for their commitment to longevity solutions rooted in the highest level of science”.
“Longevity is about living healthier for longer and L’Oréal has been working for a decade to understand and anticipate what this could mean for beauty,” said Barbara Lavernos, Deputy Chief Executive Officer and in charge of Research, Innovation and Technology, L’Oréal. “Longevity is a new definition of beauty, at the intersection of different scientific disciplines, from decoding biological markers to analyzing external exposure. Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.”
"We have been an investor in Timeline since 2019 and continue to be very impressed with the team and stand behind the exponential potential that the Mitopure technology holds for nutrition to help people age better,” said Anna Mohl, CEO of Nestlé Health Science “We’re excited to have L’Oréal join as an investor and strategic partner to bring this technology to new heights and extend its applications.”
About Timeline
Timeline (parent company Amazentis) is a pioneering Swiss health science company committed to revolutionizing the longevity industry with its groundbreaking, clinically proven, proprietary ingredient Mitopure®. Offering a comprehensive approach to cellular health, Timeline incorporates the benefits of Mitopure inside its next generation nutritional supplements and topical skin health products. With more than a decade of expertise in aging science research, Timeline seeks to push the boundaries of human healthspan, contributing to a future where everyone can live longer, healthier lives. The company is backed by over 15 years of research by distinguished scientists, multiple clinical studies, over 50 patents and Nestlé Health Science has been an investor since 2019. More information on www.timelinenutrition.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117576326/en/
Contact information
Press Contact:
Chris Rinsch, President and Co-Founder, Timeline
Federico Luna, Chief Marketing Officer, Timeline
press@timelinenutrition.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9% 15.6% -241 bps -306 bps Net income attributable to SLB - GAAP basis $797 $1,095 $1,068 -27% -25% Diluted EPS - GAAP basis $0.58 $0.77 $0.74 -25% -22% Adjusted EBITDA* $2,020 $2,382 $2,057 -15% -2% Adjusted EBITDA margin* 23.8% 25.7% 23.6% -186 bps 18 bps Pretax segment operating income* $1,556 $1,918 $1,649 -19% -6% Pretax segment operating margin* 18.3% 20.7% 18.9% -232 bps -60 bps Net income attributable to SLB, excluding charges &
Corona, The World’s Most Valuable Beer Brand 1 , Announces Its 100-Year Anniversary with Global Celebration25.4.2025 11:00:00 EEST | Press release
Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive list of the top 100 beaches in the world to visit, and a signed multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro — all offering people across the globe opportunities to connect with their beach side. “For 100 years, Corona has
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 10:28:00 EEST | Press release
Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom